0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-211.53%PremiumFeb 21, 2025Expiry Date3.40Intrinsic Value100Multiplier88DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Evogene Stock Discussion
Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results
LAV321demonstrated strong results in its third consecutive year of field trials in Europe
REHOVOT, Israel, Nov. 19, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced significant progress in the development of its LAV321 bio-fungicide, targeti...
Evogene Announces Collaboration With Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design
Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
Following a successful first year, Israel Innovation Authority (IIA) approved financing second year of collaboration
HAZEVA and REHOVOT, Israel, Oct. 8, 2024/PRNewswire/ -- Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable aquaculture and biote...
37 MINUTES AGO, 7:00 AM EDT
VIA PR NEWSWIRE
The technology aims to reduce application costs, extend shelf life, and prolong bacterial viability after field application
REHOVOT, Israel, Sept. 30, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of ...
No comment yet